Holen Sie sich die Stockscreener-App
6.32
6.96%
0.43
Schlusskurs vom Vortag:
$5.89
Offen:
$5.9
24-Stunden-Volumen:
432.98K
Relative Volume:
0.45
Marktkapitalisierung:
$141.91M
Einnahmen:
$146.07M
Nettoeinkommen (Verlust:
$-196.04M
KGV:
-0.3802
EPS:
-16.621
Netto-Cashflow:
$-75.37M
1W Leistung:
+18.87%
1M Leistung:
-28.16%
6M Leistung:
+2.28%
1J Leistung:
+63.22%
1-Tages-Spanne:
$5.85
$6.55
1-Wochen-Bereich:
$5.31
$6.55
52-Wochen-Spanne:
$3.56
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Firmenname
Karyopharm Therapeutics Inc
Sektor
Branche
Telefon
617-658-0600
Adresse
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
6.295 | 132.78M | 146.07M | -196.04M | -75.37M | -16.62 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.75 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.75 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.04 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Rodman & Renshaw | Buy |
| 2026-02-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-13 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-01-19 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-07-23 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-05 | Bestätigt | Robert W. Baird | Outperform |
| 2019-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Bestätigt | BofA/Merrill | Underperform |
| 2019-02-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-05-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-04-02 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2016-09-08 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Hochstufung | Jefferies | Hold → Buy |
| 2016-08-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-28 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
RA Capital (NASDAQ: KPTI) and partners report 9.99% stake in Karyopharm - Stock Titan
Commodore Group discloses 1.95M KPTI stake; 19,618,032 shares O/S - Stock Titan
KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 20.9% in March - MarketBeat
Will Karyopharm Therapeutics Inc benefit from green energy policiesInsider Buying & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Piper Sandler Lowers Price Target for Karyopharm Therapeutics (K - gurufocus.com
Piper Sandler Reaffirms "Overweight" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
Karyopharm stock price target cut to $8 by Piper Sandler on trial results - ca.investing.com
Karyopharm Therapeutics Inc (KPTI) Stock Price, Quote, News & History - benzinga.com
Karyopharm Strengthens Liquidity With New Equity Financing - tipranks.com
Karyopharm Therapeutics raises $30 million in private placement with RA Capital By Investing.com - Investing.com South Africa
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar? - Yahoo Finance
Karyopharm Therapeutics raises $30 million in private placement with RA Capital - investing.com
HC Wainwright Has Optimistic Outlook of KPTI Q1 Earnings - MarketBeat
Karyopharm Therapeutics raises ~$30M in private placement, adds ~$19.8M via ATM - TradingView
Karyopharm (NASDAQ: KPTI) completes $30M private placement and ATM sale - Stock Titan
Karyopharm: Putting The Phase 3 Trial In Context (NASDAQ:KPTI) - Seeking Alpha
Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data - Yahoo Finance
KPTI: Baird Lowers Price Target, Maintains Outperform Rating | K - GuruFocus
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $15.00 at Robert W. Baird - MarketBeat
HC Wainwright Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $8.00 - MarketBeat
H.C. Wainwright cuts Karyopharm stock price target on trial results By Investing.com - Investing.com Canada
HC Wainwright & Co. Lowers Price Target on Karyopharm Therapeuti - GuruFocus
Karyopharm raises $30M in private placement with RA Capital By Investing.com - Investing.com Australia
Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark - Sahm
Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-03-25 - Seeking Alpha
Karyopharm myeloma drug yields mixed data in myelofibrosis trial - BioPharma Dive
Karyopharm’s myelofibrosis trial meets one of two primary goals By Investing.com - Investing.com India
KPTI Shares Fall Following Varied Results from Phase III Myelofibrosis Combination Study - Bitget
Karyopharm Therapeutics falls as pivotal trial hits spleen goal but misses symptom mark - msn.com
Leerink cuts Karyopharm stock price target on mixed trial data By Investing.com - ca.investing.com
Why Is Karyopharm Therapeutics Stock Trading Lower Today?Karyopharm Therapeutics (NASDAQ:KPTI) - Benzinga
Karyopharm’s Phase 3 SENTRY Trial Shows Significant Spleen Reduction and Promising Overall Survival in Myelofibrosis with Selinexor Plus Ruxolitinib 1 - Minichart
Karyopharm phase III Sentry entry bucks rux in MF; to FDA next - BioWorld MedTech
Karyopharm, looking to jump-start Xpovio, reports mixed results in myelofibrosis - Fierce Pharma
Karyopharm research and financing developments - The Pharma Letter
Karyopharm shares rise 10% after mixed Phase 3 SENTRY trial results - MSN
KPTI Stock Faces Uncertainty Amid Financial Challenges - StocksToTrade
Karyopharm Therapeutics SENTRY Trial Hits Spleen Endpoint, Shows Early Survival Signal in Myelofibrosis - MarketBeat
RBC Capital maintains Outperform on Karyopharm stock after trial data By Investing.com - Investing.com Australia
RBC Capital maintains Outperform on Karyopharm stock after trial data - Investing.com
Karyopharm Therapeutics (KPTI) Stock Plunges 12.71% on $30M Financing Announcement - Blockonomi
Karyopharm (KPTI) Announces Positive Phase 3 Trial Results for S - GuruFocus
Karyopharm Therapeutics Inc. (KPTI) Stock: Drops 12.71% After $30M Private Placement Deal - CoinCentral
Karyopharm Shares Jump 10% Following Mixed Phase 3 Trial Outcomes on Myelofibrosis Treatment - stockinvest.us
Why Did KPTI Stock Tank 13% In Pre-Market Today? - Stocktwits
Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Karyopharm Therapeutics Inc-Aktie (KPTI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rangwala Reshma | EVP & Chief Medical Officer |
Mar 02 '26 |
Sale |
9.41 |
5,066 |
47,669 |
56,739 |
| Paulson Richard A. | President and CEO |
Mar 02 '26 |
Sale |
9.41 |
12,361 |
116,311 |
267,030 |
| Poulton Stuart | EVP, Chief Development Officer |
Feb 17 '26 |
Sale |
8.63 |
378 |
3,262 |
99,429 |
| Macomber Lori | EVP, CFO & Treasurer |
Feb 03 '26 |
Sale |
6.30 |
1,626 |
10,244 |
85,105 |
| Abate Kristin | Chief Accounting Officer |
Jan 28 '26 |
Sale |
7.03 |
50 |
352 |
22,622 |
| Abate Kristin | Chief Accounting Officer |
Jan 21 '26 |
Sale |
5.96 |
265 |
1,579 |
22,580 |
| Abate Kristin | Chief Accounting Officer |
Oct 01 '25 |
Sale |
6.30 |
362 |
2,279 |
10,046 |
| Paulson Richard A. | President and CEO |
Sep 15 '25 |
Sale |
6.43 |
1,257 |
8,083 |
84,046 |
| Mano Michael | SVP, General Counsel&Secretary |
Sep 15 '25 |
Sale |
6.43 |
234 |
1,505 |
21,425 |
| Poulton Stuart | EVP, Chief Development Officer |
Sep 15 '25 |
Sale |
6.43 |
401 |
2,578 |
27,710 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):